ClinicalTrials.gg

Program

dazodalibep

Also written as “VIB4920”, “Dazodalibep” and “Inebilzumab+VIB4920”.

Its studies are mostly in Sjogren's Syndrome · Arthritis, Rheumatoid, led by 2 companies.

Furthest: phase 3, since Oct 23, 20239 company-led studies, 2 open or runningNext primary completion: Dec 11, 2029 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Amgen82 open or runningphase 3since Oct 23, 2023May 3, 2016Dec 11, 2029phase 3 · NCT06747949
AstraZeneca10 open or runningphase 1since May 27, 2014May 27, 2014none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 27, 2014First study: phase 1 study in Healthy VolunteerNew to AstraZenecaAstraZeneca · NCT02151110 · 59 enrolled · United Kingdom
  2. May 3, 2016Amgen's first study: phase 1 study in Arthritis, RheumatoidNew to AmgenAmgen · NCT02780388 · 57 enrolled · United States, Poland
  3. Aug 2, 2019Phase 2 study in Rejection, PsychologyAmgen · NCT04046549 · 25 enrolled · United States
  4. Oct 2, 2019Phase 2 study in Sjogren's SyndromeAmgen · NCT04129164 · 183 enrolled · United States, Argentina, France and more
  5. Nov 5, 20192 phase 2 studiesAmgen · NCT04174677, NCT04163991
  6. Oct 23, 2023Phase 3 study in Sjogren's SyndromeAmgen · NCT06104124 · 651 enrolled · United States, Argentina, Australia and more
  7. Jan 30, 2024Phase 3 study in Sjogren's SyndromeAmgen · NCT06245408 · 434 enrolled · United States, Argentina, Australia and more
  8. Dec 19, 2024Phase 3 study in Sjogren's SyndromeAmgen · NCT06747949 · 844 planned · United States, Argentina, Australia and more

Ahead

  1. Dec 11, 2029Primary completion: phase 3 study in Sjogren's SyndromeAmgen · NCT06747949

TargetBeta

CD40LG →read by rule
“CD40 ligand antagonist”ChEMBL 37, by rule

Other programs on CD40LG

ProgramCompanyFurthest phaseStudies
frexalimabSanofiphase 311
dapirolizumab pegolruleUCBphase 38
tegoprubartruleeledon-pharmaceuticalsphase 38
ravagalimabruleAbbViephase 24
OPT101ruleop-t-llcphase 24
TNX-1500ruleTonix Pharmaceuticalsphase 11

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06747949Sjogren's Syndrome · United States, Argentina, Australia and more3RecruitingAmgenDec 11, 2029844
NCT06245408Sjogren's Syndrome · United States, Argentina, Australia and more3Active, not recruitingAmgenOct 22, 2026434
NCT06104124Sjogren's Syndrome · United States, Argentina, Australia and more3CompletedAmgenJul 23, 2026651
NCT04163991Arthritis, Rheumatoid · United States, Poland2CompletedAmgenDec 28, 202178
NCT04174677Highly Sensitized Patients on Waiting List for Kidney Transplantation · United States2WithdrawnAmgenDec 20210
NCT04129164Sjogren's Syndrome · United States, Argentina, France and more2CompletedAmgenSep 1, 2022183
NCT04046549Rejection, Psychology · United States2CompletedAmgenJul 18, 202225
NCT02780388Arthritis, Rheumatoid · United States, Poland1CompletedAmgenMay 21, 201857
NCT02151110Healthy Volunteer · United Kingdom1CompletedAstraZenecaMay 9, 201659

How it is read

Names in the registry

  • “VIB4920”, 5 entries
  • “Dazodalibep”, 3 entries
  • “Inebilzumab+VIB4920”, 1 entry
  • “MEDI4920 3 mg”, 1 entry
  • “MEDI4920 10 mg”, 1 entry

Codes read as this program: VIB4920.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.